Journal article icon

Journal article : Review

How should we use convalescent plasma therapies for the management of COVID-19?

Abstract:

Convalescent plasma (CP) from blood donors with antibodies to severe acute respiratory syndrome coronavirus 2 may benefit patients with COVID-19 by providing immediate passive immunity via transfusion or by being used to manufacture hyperimmune immunoglobulin preparations. Optimal product characteristics (including neutralizing antibody titers), transfusion volume, and administration timing remain to be determined. Preliminary COVID-19 CP safety data are encouraging, but establishing the clin...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1182/blood.2020008903

Authors


More by this author
Role:
Author
ORCID:
0000-0001-7527-2340
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Role:
Author
ORCID:
0000-0003-4309-9162
More by this author
Role:
Author
ORCID:
0000-0001-9698-7185
Publisher:
American Society of Hematology Publisher's website
Journal:
Blood Journal website
Volume:
137
Issue:
12
Pages:
1573-1581
Publication date:
2020-11-07
Acceptance date:
2020-11-09
DOI:
EISSN:
1528-0020
ISSN:
0006-4971
Pmid:
33202419
Language:
English
Keywords:
Subtype:
Review
Pubs id:
1146163
Local pid:
pubs:1146163
Deposit date:
2022-06-20

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP